Stable Istotope Labelled Evinacumab Biosimilar – Anti-ANGPTL3 mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Stable Istotope Labelled Evinacumab Biosimilar - Anti-ANGPTL3 mAb - Research Grade |
|---|---|
| Source | CAS 1446419-85-7 |
| Species | Homo sapiens |
| Expression system | Mammalian cells |
| Purity | >95% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue Ice |
| Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Aliases /Synonyms | REGN 1500 |
| Reference | PX-TA1369-SIL |
| Related Products | PX-P4695 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG4-kappa |
| Clonality | Monoclonal Antibody |
| Format | Lyophilized |
| Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
| Isotopic Enrichment | 99% |
| Stability | 1 year |
General information on Anti-ANGPTL3[Homo sapiens] (Evinacumab) Monoclonal Antibody
Evinacumab is a recombinant human IgG4 monoclonal antibody targeting human angiopoietin-like protein 3 (ANGPTL3). The ANGPTL protein family has many physiological functions-including the regulation of lipid metabolism. It has been noted that the loss-of-function mutation of ANGPTL3 leads to hypolipidemia and subsequently reduces cardiovascular risk, while increased function seems to be related to cardiovascular risk. Evinacumab has been used to treat homozygous familial hypercholesterolemia (HoFH). It has been sold under the Evkeeza brand name.
Contact us
Send us a message from the form below
Reviews
There are no reviews yet.